傅蓉

傅蓉,中国药科大学兴药青创学者(2021-2025),特聘研究员,博士生导师。入选江苏省第六期“333高层次人才培养工程第三层次培养对象和江苏省科协青年科技人才托举工程。2012年获得理学博士,同年入职中国药科大学基础医学与临床药学学院。20156月在美国加州伯克利分校生物工程院以访问学者身份工作1年。目前的主要研究方向包括:基于条件敲除转基因动物模型的血管发育与重构分子机制研究、肿瘤转移和耐药发生机制与逆转策略研究、抗肿瘤靶向小分子创新药物发现与研究。入职以来,主持国家自然科学基金青年项目、江苏省自然科学基金青年项目各1项。参与多项国家级省部级课题及抗肿瘤新药的研发工作。以第一作者或通讯作者在The Journal of Clinical InvestigationIF 14.808)、Nature CommunicationsIF 14.9192)、Science AdvancesIF 14.136, British Journal of PharmacologyIF 7.7302)等国际期刊发表SCI研究论文。

 

发表论文:

1. Rong Fu#, Yi Li#, Nan Jiang#, Bo-Xue Ren#, Chen-Zi Zang, Li-Juan Liu, Wen-Cong Lv, Hong-Mei Li, Stephen J. Weiss, Zheng-Yu Li, Tao Lu, Zhao-Qiu Wu*. Inactivating endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies. The Journal of Clinical Investigation, 2020, 130(3):1252-1270. 并列第一作者排名第一IF: 14.808

2. Rong Fu#, Wen-Cong Lv#, Ying Xu#, Mu-Yun Gong#, Xiao-Jie Chen, Nan Jiang, Yan Xu, Qing-Qiang Yao, Lei Di, Tao Lu, Li-Ming Wang, Ran Mo, Zhao-Qiu Wu*. Endothelial ZEB1 promotes angiogenesis-dependent bone formation and reverses osteoporosis. Nature Communications,2020, 11(1): 460. 并列第一作者排名第一IF: 14.919

3. Rong Fu#, Chen-Feng Han#, Ting Ni#, Lei Di#, Li-Juan Liu, Wen-Cong Lv, Yan-Ran Bi, Nan Jiang, Yin He, Hong-Mei Li, Shui Wang, Hui Xie, Bao-An Chen, Xiao-Sheng Wang, Stephen J. Weiss, Tao Lu, Qing-Long Guo, Zhao-Qiu Wu*. A ZEB1/p53 signaling axis in stromal fibroblasts promotes mammary epithelial tumours. Nature Communications,2019, 10(1): 3210.并列第一作者排名第一IF: 11.878

4.Hong-Mei Li#, Yan-Ran Bi#, Yang Li#, Rong Fu#, Wen-Cong Lv, Nan Jiang, Ying Xu, Bo-Xue Ren, Ya-Dong Chen, Hui Xie, Shui Wang, Tao Lu, Zhao-Qiu Wu. A potent CBP/p300-Snail interaction inhibitor suppresses tumor growth and metastasis in wild-type p53-expressing cancer. Science Advances, 2020, 6(17): eaaw8500.并列第一作者排名第四,IF: 14.136

5. Bo-Xue Ren#, Yang Li#, Hong-Mei Li#, Tao Lu, Zhao-Qiu Wu*, Rong Fu*.The Antibiotic Drug Trimethoprim Suppresses Tumor Growth and Metastasis via Targeting Snail. British Journal of Pharmacology, 2022, 179(11): 2659-267.并列通讯作者排倒数第一,IF: 8.739

6. Rong Fu#, Yi-Wei Zhang#, Hong-Mei Li#, Wen-Cong Lv, Li Zhao, Qing-Long Guo, Tao Lu, Stephen J Weiss, Zhi-Yu Li, Zhao-Qiu Wu*. LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment. British Journal of Pharmacology,2018, 175(14): 3034-3049.并列第一作者排名第一,IF: 7.730

7. Xiao-Ping Wang#, Qing-Long Guo#, Lei Tao, Yan Chen, Teng An, Zhen Chen, Rong Fu*. E platinum, a newly synthesized platinum compound, induces apoptosis through ROS-triggered ER stress in gastric carcinoma cells. Molecular Carcinogenesis, 2017, 56(1): 218-231. 通讯作者,IF: 4.7

8. Rong Fu#, Qiu-Juan Wang, Qing-Long Guo*, Jing-Yi Xu, Xiao-Ming Wu. XJP-1 protects endothelial cells from oxidized low-density lipoprotein-induced apoptosis by inhibiting NADPH oxidase subunit expression and modulating the PI3K/Akt/eNOS pathway. Vascular Pharmacology, 2013, 58(1-2): 78-86.第一作者,IF: 4.6

9. Rong Fu#, Tian-Hua Yan, Qiu-Juan Wang, Qing-Long Guo*, He-Quan Yao, Xiao-Ming Wu, Yang Li. Suppression of endothelial cell adhesion by XJP-1, a new phenolic compound derived from banana peel. Vascular Pharmacology, 2012, 57(2-4): 105-112.第一作者IF: 4.6

10. Rong Fu#, Zhen Chen#, Qiu-Juan Wang, Qing-Long Guo*, Jing-Yi Xu, Xiao-Ming Wu. XJP-1, a novel ACEI, with anti-inflammatory properties in HUVECs. Atherosclerosis, 2011, 219(1): 40-48.并列第一作者排名第一,IF: 4.5

 

获奖:

以第二完成人获2021年江苏省高等学校科学技术研究成果一等奖(2/4)。

著作:

以第一副主编身份编写《恶性肿瘤多药耐药的逆转》201311由东南大学出版社出版。

 

专利申请:

1、吴照球、傅蓉、莫然;ZEB1基因的用途及相关药物;申请日期:2019-9-16

申请号:CN201910870592.5

2、吴照球、傅蓉、任博雪;甲氧苄啶的医药新用途;申请日期:2020-12-14

申请号:202011463916.2

 

联系方式:手机18061476903,邮箱furong@cpu.edu.cn,南京市江宁区龙眠大道639号,中国药科大学江宁校区医学实验楼107